SGLT2 inhibitors are derivatives of naturally occurring compounds and differ in structure, potency, and dosing.

“all of these uh giflosens if you will or glyph flozins uh have kind of a similar structure right which is this sort of glucose ring with an aromatic group and then they differ basically around that and these differences produce obviously allow you to have you know did drug companies to make different versions of drugs from an IP perspective but they also you know tend to be dosed differently um and uh and and therefore they that reflects a very different potency of the drugs as well”